A new drug that prevents hot flushes during menopause has been approved for use in the UK and the EU.
Veoza, also known as fezolinetant, has been given the go-ahead by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Commission after it was approved for use by the US Food and Drug Administration earlier this year.
Hot flushes, also known as vasomotor symptoms, are a common symptom of menopause that often feels like a sudden flare of heat, paired with sweating and flushed skin. Worldwide, more than half of women between 40 to 64 years experience them, with rates in Europe ranging from 56 per cent to 97 per cent.
Before menopause, there is a balance between oestrogens and a protein made by the brain, known as neurokinin B (NKB), that regulates the brain’s temperature control centre. As the body goes through menopause, oestrogen levels decline and this balance is disrupted, which can lead to hot flushes.
Veoza, developed by the Japanese drug maker Astellas Pharma, reduces the number and intensity of hot flushes and night sweats by blocking neurokinin-3.
“Hot flushes and night sweats caused by menopause are common and can have a significant impact on a woman’s daily life,” explained Julian Beach, the interim executive director of healthcare quality and access at the MHRA.
“We are therefore pleased to have authorised Veoza (fezolinetant) for hot flushes and night sweats caused by menopause via our reliance procedure.
“No medicine would be approved unless it met our expected standards of safety, quality and effectiveness and we continue to keep the safety of all medicines under close review.”
Professor Rossella Nappi, associate professor of obstetrics and gynaecology and director of the gynaecological endocrinology and menopause unit IRCCS San Matteo Foundation, University of Pavia, said: “I’ve been awaiting the marketing authorisation of fezolinetant.
“I’m happy to see this advancement in women’s health and that my patients will soon have this new non-hormonal treatment option available to better control their moderate to severe vasomotor symptoms.”
The coolest brand in hot flash relief: behind Femography’s menopause clothing revolution
In an era when menopause was seldom addressed, Femography courageously launched Become
In the realm of women’s health, an exciting revolution is underway, and at its forefront is Femography, a trailblazing brand in the femtech industry.
Backed by a formidable apparel conglomerate and embraced by women worldwide, Femography is more than just a brand – it’s a movement reshaping the menopause apparel industry. This feature dives into Femography’s journey and highlights a ‘cool’ gift idea for your friends and loved ones – figuratively and literally.
Powered by an apparel giant: a leap in women’s health
Femography distinguishes itself in the femtech space with the robust backing of MAS Holdings, a titan in South Asia’s apparel tech industry. This partnership propels Femography forward in a sector where a mere three per cent of women’s health-focused businesses have secured financing since 2011.
It marks a significant step in filling a gap in women’s health — a crucial but often overlooked area — positioning Femography as a visionary leader.
Scientific breakthrough meets lifestyle
The cornerstone of Femography’s success lies in its groundbreaking patented Anti-Flush™ Technology, ingeniously crafted to tackle the three stages of a hot flash, a predominant symptom of menopause.
This innovation transcends the boundaries of science, offering lifestyle solutions that blend seamlessly into everyday life. It’s this unique fusion of scientific ingenuity and practical utility that sets Femography apart, carving out its niche in the market.
Femography’s holistic product line
Femography’s product development approach is comprehensive and thoughtful. Their expansive product line, including Anti-Flush™ sleepwear, camisoles, panties, loungewear, tank tops, leggings and ultra absorbent underwear, is designed with the utmost care to ease menopause-related discomforts.
Each item in this diverse array is crafted to empower women, enabling them to lead fulfilling lives without the burdens of menopause symptoms.
Enter Become: pioneering change with Femography’s consumer brand
In an era when menopause was seldom addressed, Femography courageously launched Become, its consumer brand dedicated to menopause apparel. This bold initiative has led the way for seven years, transforming societal perceptions and dismantling stigmas around menopause.
Become has not only brought relief to countless women but has also been instrumental in evolving the market, cultivating a space where menopause is openly discussed and managed with dignity and understanding.
A cool gift idea: embrace the holiday spirit with Become
This holiday season, Femography invites you to reimagine gift-giving. Sharing Become’s revolutionary clothing with friends is a wonderful way to support those experiencing menopause. It’s more than a gift; it’s an expression of care, offering real comfort in daily life.
This thoughtful gesture of gifting cooling apparel is not only practical but also a symbol of empathy and unity. And what could be cooler than presenting a gift that brings literal and figurative coolness to someone’s life?
Femography’s broader impact as a leading B2B partner
Femography’s journey in the femtech revolution is marked not just by its technological innovation but also by its deep understanding of consumer needs.
While the holiday season offers a moment to focus on individual gifting, the broader, year-round scope of Femography’s impact lies in its role as a powerful B2B partner in the health and apparel sectors. This dual focus reflects Femography’s commitment to enhancing the lives of individual women and driving forward the industry as a whole.
By offering cutting-edge solutions like their Anti-Flush™ technology, Femography has set new standards in menopause apparel. Their innovative approach extends beyond product development to fostering meaningful collaborations with businesses and brands.
Femography amplifies its impact through these partnerships, making women’s health solutions more accessible and creating a global ripple effect of well-being and empowerment.
Telehealth platform launches corporate wellness programme to support menopausal women
Winona Corporate Wellness aims to assist businesses in fostering a supportive and inclusive environment
The US menopause telehealth company Winona has announced a new initiative to support menopausal women in the workplace.
The corporate wellness programme Winona Corporate Wellness aims to assist businesses in fostering a supportive and inclusive environment for women approaching menopause within their organisations.
Recognising the importance of addressing menopause-related challenges in the workplace, the company says it has designed the programme to empower women and enhance their wellbeing during a transformative phase of their lives.
“Empowering women through education and support during the menopause transition is not just our mission; it’s our obligation,” shared Winona’s head of PR, Angela Stubbs.
“When we share knowledge and resources, we empower women to reclaim their health, happiness, and vitality.
“Winona Corporate Wellness is not only a commitment to the wellbeing of women but also a strategic investment in a diverse and thriving workforce.
“By providing companies with the tools and resources they need to support their menopausal employees, Winona aims to drive positive change across workplaces and industries.”
Every day in the US 6,000 women hit menopause, which is defined as starting 12 months after a woman’s last period.
On average, they reach menopause at 51, but perimenopause can occur much earlier. This lead-up period, when hormones can fluctuate wildly and symptoms may be at their worst and most unpredictable, lasts four to seven years, although in some cases it can extend as long as a decade.
The Winona Corporate Wellness programme aims to provide women with resources, guidance, and a platform for open conversations to allow companies to champion women’s health and productivity.
The initiative also includes expert-led seminars and workshops to educate employees and management about menopause as well as telehealth services and virtual consultations with healthcare professionals specialising in menopause care.
TaraCares agrees MIMOSA™ pilots and launches Menopause Intelligence™ Maturity Index for corporates
TaraCares aims to empower employers to design individualised workplace practices
TaraCares has announced its first MIMOSA™ pilots ahead of launching Menopause Intelligence™ Maturity Index.
TaraCares Global, the developer behind the virtual menopause health literacy and workplace wellbeing platform MIMOSA™, aims to reimagine how female individuals of all ages, ethnicities and genders navigate their unique menopause journey.
A B2B HealthTech SaaS platform, MIMOSA™ is currently available through employers.
Individuals receive user-centric validated research continually personalised to their health profile, real-time history and health trace across 29 health variables extracted from analysing large scale high-quality research on menopause funded by Innovate UK and the National Institute for Health and Care Research (NIHR). This includes physiological and psychological health alongside other life stressors.
MIMOSA™ enables employers to transform from Menopause Friendly to Menopause Intelligent™, helping them benefit from sophisticated signals on the needs and diversity of their menopausal workforce.
This, TaraCares argues, in turn empowers employers to design individualised workplace practices and prevent costs from support built for the average menopause experience.
Already available on Android and iOS in 16 countries, the platform has received positive feedback from clinicians and individual users during the private launch that witnessed a user engagement rate of 84.38 per cent in 11 countries.
In an effort to expand, TaraCares has signed the first pilot for its MIMOSA™ platform with the Hampshire and Isle of Wight (HIOW) Integrated Care Services (ICS) beginning September 2023.
Jyoti Sharma, founder and CEO of TaraCares, said: “We are addressing the menopause health crisis by disrupting the menopause market and the enterprise software employee/people experience economy with MIMOSA™, creating a new category for menopause health literacy and workplace wellbeing.”
Hilary Todd, project director for the Hampshire and Isle of Wight ICS Employee Health and Wellbeing Programme, which delivers health and wellbeing support and services to 55,000 NHS and primary care employees, added: “No two experiences of menopause are the same, so we are excited to offer MIMOSA™ to help our people gain personalised insights that support them in understanding and managing their menopause.
“The pilot complements our menopause programme, which is designed to help colleagues feel more confident and ultimately more empowered. We hope that the personalised insights gained make a valuable difference for our people.”
Evidence and feedback
In the US$4.2tn wellness market comprising personalised medicine, healthy eating, nutrition and workplace wellbeing solutions, TaraCares has been unstoppable in integrating its academic and scientific research evidence with tech and clear pathways to value through its collaboration with the Wessex Academic Health Science Network (AHSN) and the York Health Economics Consortium (YHEC).
Evidence and feedback is central to TaraCares’s ethos. The company has collaborated with the Academic Health Sciences Networks (AHSN) in England to stay aligned with building for the NHS and has partnered with Gemma Snell, innovation and industry programme manager at NHS Innovation Service.
“Working with Gemma Snell as the innovation lead at the Wessex AHSN has been instrumental in critical analysis to develop MIMOSA™ further; collaborating on the value proposition, arranging market insights opportunities with GPs with special interest in menopause as well as a local NHS ICB Peoples Programme,” said Sharma.
Snell, who has spent over 10 years working in the NHS improving clinical pathways and helping health systems to provide the best care and support to patients, added: “I have been pleased to collaborate with Jyoti to realise the potential of MIMOSA™ in supporting women and female individuals to understand and manage their unique menopause so that they can take control and keep living life to the full as they transition through it”
Wessex AHSN’s Insight team also provided expertise around designing evaluation studies, funding opportunities and bid preparations.
Sharma has spent 22 years designing and delivering large-scale people-centric organisational transformations across the Americas, Europe, Middle East and Africa.
She was in her third year of individual differences in menopause research when she decided to found her start-up in May 2022, declining PhD offers from prestigious universities in England and Australia.
“This felt like my life-long PhD,” Sharma explained. “I traded in the Dr title for the translation of our research with tech to deliver improved health for individuals, families, organisations and ultimately our society through this inevitable transition in a female individual’s life.”
After launching the first version of its proprietary Menopause Intelligence™ Maturity Index, Sharma and her team are now focusing on an equity seed investment round that she says will help fuel their rapid growth and expansion into the US and Canada.
- Lawyers warn of discrimination risks around lack of menstrual health support in the workplace
- OB/GYN-founded vitamin company pledges US$10m to improve women’s health research
- New treatment could ‘disrupt’ growth of breast cancer tumours
- The slippery slope of presumed consent in post-humous reproductive health cases
- Women’s health content censored and blocked on social media
Receive updates from Femtech World
- News2 weeks ago
Research validates new technique to detect ovarian cancer
- News2 days ago
French femtech start-up raises €5m to expand hybrid healthcare model
- Special4 weeks ago
Femtech funding: what investors want you to know in 2024
- News2 weeks ago
Health companies use ‘misleading’ feminist narratives to market useless products, researchers find
- News3 weeks ago
FDA clears Hologic’s cervical cancer screening system
- News1 week ago
Tech4Eva launches its fourth edition and call for application
- News2 weeks ago
South Korean start-up closes undisclosed funding round to develop AI embryo selection tool
- Insider Insight1 day ago
Insider Insight: Margaret Zablocka, founder and CEO of Onoco